A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial) Meeting Abstract
| Authors: | Hanna, G. J.; Batista, C. P.; Ho, A. L.; Gillison, M. L.; Adkins, D.; Dayoub, A.; Martell, B.; Leoni, M.; Dale, S.; Nie, K.; Dmitrienko, A. |
| Abstract Title: | A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial) |
| Meeting Title: | 113th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 82 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2022 Apr 8-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-06-15 |
| Language: | English |
| ACCESSION: | WOS:000892509502192 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2022-CT253 |
| Notes: | Meeting Abstract: CT253 -- Source: Wos |
